GeoVax Labs, Inc. will report third quarter 2024 financial results and host a live conference call and webcast at 4:30 p.m. ET to provide a corporate update and discuss financial results, offering insights into the company's development of novel vaccines for infectious diseases and therapies for solid tumor cancers.
This news matters as it provides an opportunity for investors and stakeholders to gain insights into GeoVax's financial performance and ongoing developments in the development of novel vaccines for infectious diseases and therapies for solid tumor cancers, including a next-generation COVID-19 vaccine.
